published meta-analysis   sensitivity analysis   studies

bromhexine in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsAnsarin, 2020 0.09 [0.00; 1.68] 0.09[0.00; 1.68]Ansarin, 202010%78NAnot evaluable clinical deteriorationdetailed resultsLi T, 2020 0.48 [0.01; 27.44] 0.48[0.01; 27.44]Li T, 202010%18NAnot evaluable clinical improvement (21-day)detailed resultsLi T, 2020 2.09 [0.04; 119.96] 2.09[0.04; 119.96]Li T, 202010%18NAnot evaluable hospital dischargedetailed resultsLi T, 2020 10.00 [1.03; 97.50] 10.00[1.03; 97.50]Li T, 202010%18NAnot evaluable mechanical ventilationdetailed resultsAnsarin, 2020 0.09 [0.01; 0.73] Li T, 2020 0.40 [0.04; 3.90] 0.18[0.04; 0.84]Ansarin, 2020, Li T, 202020%96seriousnot evaluable viral clearance by day 14detailed resultsLi T, 2020 1.00 [0.03; 34.67] 1.00[0.03; 34.67]Li T, 202010%18NAnot evaluable ICU admissiondetailed resultsAnsarin, 2020 0.14 [0.03; 0.67] 0.14[0.03; 0.67]Ansarin, 202010%78NAnot evaluable severe adverse eventsdetailed resultsAnsarin, 2020 1.00 [0.02; 51.70] 1.00[0.02; 51.70]Ansarin, 202010%78NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-03-29 06:40 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 688 - roots T: 290